Tag Archives: Transgenomic

Horizon Discovery Group and Transgenomic announced a new original equipment manufacturer agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed.

January 2014—Transgenomic in October announced the results of a research collaboration with MD Anderson Cancer Center employing the company’s ICE COLD-PCR platform. This interim analysis demonstrates that in a high percentage of patients with advanced cancers, the same genetic mutations were detected in cell-free DNA present in the blood as were originally found in primary tumors. In a subset of patients followed over time, detection of mutations in cfDNA correlated with response to therapy or disease progression.

December 2013—Transgenomic has entered into a collaborative agreement with PerkinElmer to market and distribute Transgenomic’s oncology diagnostic test portfolio of products in territories outside the United States.